Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of single-dose intravenous BRL-101 for transfusion-dependent beta-thalassemia
CTR20222413Phase 2Active
- Sponsor
- BRL Medicine Inc.
- Start
- Mar 2025
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of BRL-101 in beta thalassemia, sponsored by BRL Medicine Inc.. Started Mar 2025; status: active.
02
Drugs
BRL-101
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on CTR20222413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222413.